A simple, rapid, sensitive and specific liquid chromatographic method was developed and validated for the determination of curcumin in human plasma. Berberine was used as the internal standard. Chromatographic separation was achieved on a Zorbax Eclipse C 18 column at 408 8 8 8 8C, with a mobile phase consisting of 1% acetic acid (pH 3 adjusted with 50% triethanolamine): acetonitrile (55:45), at a flow rate of 1.25 mL/min. The method was validated for precision, accuracy, linearity, lower limit of quantification (LLOQ) and extraction efficiency according to the International Conference on Harmonization guidelines. The method was successfully developed with an LLOQ of 10 ng/mL and a runtime of 9 min. Linearity range was from 10 to 1000 ng/mL. Curcumin and Berberine were well separated with retention times of 8.2 + + + + + 0.2 and 1.4 + + + + + 0.1 min, respectively. Further, the method was successfully employed to study the pharmacokinetic parameters of curcumin, following oral administration of curcuminloaded hydroxy propyl cellulose (HPC) nanoparticles and curcumin suspension in female Wistar rats. Curcumin-loaded HPC nanoparticles (C max : 106.01+ + + + + 20.11 ng/mL) showed significant improvement in pharmacokinetic parameters when compared with curcumin suspension (C max : 30.13+ + + + + 0.47 ng/mL) indicating 43.73-fold increase in relative bioavailability.
Introduction
Curcumin, (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) (Figure 1a) , is a polyphenol derived from the root of turmeric (1, 2) . It is traditionally used in south and south-east tropical Asia as a dietary spice, a coloring agent and treatment for a wide variety of ailments including biliary disorders, anorexia, cough, diabetic wounds, hepatic disorders, rheumatism, sinusitis and cancer (3, 4) . However, low bioavailability (1% in rats) upon oral administration restricts its clinical use, which is due to its poor aqueous solubility and dissolution properties (5) . Curcumin is found to be stable at acidic pH attributed to its conjugated diene structure, whereas it degrades under basic conditions due to removal of proton from the phenolic group leading to the destruction of its pharmacological activity (6) .
The analytical methods used to determine curcumin concentration in biological samples include liquid chromatography (LC) with UV (7) (8) (9) (10) and tandem mass spectrometric detection (11, 12) . A High-performance liquid chromatography (HPLC-UV) assay was developed for quantitative determination of curcumin in plasma. The most sensitive sample pretreatment provided a lower limit of quantification (LLOQ) of 2.5 ng/mL. However, this sensitive method needed a large sample volume of 2 mL and the extraction solvent was chloroform, which is toxic (8) . Another HPLC-UV analytical method developed for determination of curcumin in biological samples had an LLOQ of .20 ng/mL and the run time extended beyond 11 min (9, 10) . In one of the liquid chromatography and mass spectroscopy/mass spectroscopy (LC-MS/MS) method for quantification of curcumin and its metabolite tetrahydrocurcumin in rat plasma a sample volume of 100 mL was used with an LLOQ of 0.5 ng/mL and a mean extraction recovery of 77.15%. In this method, the sample pretreatment was cumbersome that involved initial incubation of plasma samples to hydrolyze the curcumin and tetrahydrocurcumin conjugates followed by liquid-liquid extraction using ethyl acetate. (11) . Another LC-MS/MS method was used to study the oral pharmacokinetics of curcumin in rats with an LLOQ of 5 ng/mL and a run time of 5 min (12). May et al. described a method based on matrix-assisted laser desorption ionization time of flight mass spectrometry for the study of curcumin and its metabolites in mouse serum and mouse lung cell cultures (13) . Although the LC-MS/MS method can provide excellent sensitivity and short run time, the equipment is expensive and the matrix effects are difficult to overcome. Recently, a HPLC-photodiode array detector (PDA) method was reported for the determination of curcumin in rat plasma, using 96-well plates for extraction and injection volume was 50 mL (14) . Also, an ultra performance liquid chromatography (UPLC) method with an LLOQ of 2.5 ng/mL was reported, wherein the extraction efficiency was low (15) . Further, Vijaya Saradhia et al., Li et al. and Kakkar et al. reported a LC-tandem mass spectrometric method for quantification of curcuminoids in cell medium and mouse plasma (16) (17) (18) . Considering entire reported literature, the present study aims to develop a simple and sensitive LC method with a high extraction efficiency (100%) and extremely low LLOQ (10 ng/mL) for the analysis of curcumin in human plasma. Further, the efficacy of the developed method is confirmed by comparative pharmacokinetic analysis of curcumin-loaded hydroxy propyl cellulose (HPC) nanoparticles and curcumin suspension upon oral administration in female Wistar rats. Berberine (Figure 1b ) was used as an internal standard (IS) (19) .
Experimental

Instrumentation
The HPLC system consisted of a Plus Intelligent LC pump PU-2080 from Jasco (Tokyo, Japan) equipped with a Jasco UV-2075 Intelligent UV-Vis detector and a Rheodyne 7725 injector (Rheodyne, Cotati, CA, USA), along with Jasco ChromaPass Chromatography Data System Software (Version 1.8.6.1).
Chromatographic separation was achieved on a Zorbax Eclipse C 18 column (4.6 Â 150 mm, 5 mm). The column was coupled to C 18 guard column, 5 mm Agilent (4.6 Â 12.5 mm) at 408C. The mobile phase employed comprised Solvent A: 1% acetic acid adjusted to pH of 3.0 using 50% triethanolamine and Solvent B: acetonitrile. Prior to use, the mobile phase was filtered through a 0.45-mm membrane. The flow rate was adjusted to 1.25 mL/min, injection volume was 20 mL and samples were analyzed at a wavelength of 425 nm.
Materials and reagents
Curcumin (95% purity) and Berberine were gift samples from Konark Herbals Ltd., Mumbai, India, and Total Herbal Solutions Pvt. Ltd., Mumbai, India, respectively. Polyvinylpyrrolidone (PVP; K-90/D; average molecular weight: 1,300,000) and Hydroxy Propyl Cellulose and Poloxamer 188 were kindly provided by ISP Technologies, New Jersey, USA, Signet Chemical Corporation Pvt. Ltd., Mumbai, India, and BASF India Ltd., Mumbai, India, respectively. HPLC grade acetonitrile, methanol, acetic acid and triethanolamine were purchased from s.d. Fine Chemicals, Mumbai, India. 0.2 and 0.45 mm membranes were purchased from Pall Life Sciences, Mumbai, India. All other chemicals used were of analytical grade unless otherwise indicated.
Standard solutions and spiked samples Stock solutions of curcumin and IS were prepared in methanol at a concentration of 100 mg/mL separately. The curcumin stock solution was diluted with methanol to obtain working solutions of concentration ranging from 0.2 to 20 mg/mL. IS working solution (20 mg/mL) was also prepared by diluting the stock solution with methanol. All the prepared solutions were protected from light using amber-colored volumetric flask. Standard solutions (10, 25, 50, 100, 250, 500 and 1000 ng/mL) were prepared by spiking 50 mL of each working solution (0.2, 0.5, 1, 2, 5, 10 and 20 mg/mL) into 100 mL of blank plasma, 50 mL of IS and 800 mL of acetonitrile. For each validation and assay run, the calibration standards were freshly prepared from the working solutions. These standards were used to construct calibration curves for the quantification of curcumin at human plasma concentrations ranging from 10 to 1000 ng/mL. Quality control (QC) samples at four different levels were independently prepared at concentrations of 10 ng/mL (LLOQ, Lower LOQC), 50 ng/mL (LOQ, LOQ QC), 250 ng/mL (MQC, medium QC) and 1000 ng/mL of (HQC, high QC) curcumin in the same way. IS concentration was kept constant at 1000 ng/mL (HQC, high QC) throughout the study. Sample preparation procedure is described previously.
Plasma sample preparation
Fifty microliters of each of standard, unknown and QC samples were pipetted using micropipette into 2 mL eppendorf microcentrifuge tubes. To each tube, 100 mL of plasma was added. The tubes were capped and vortexed for 30 s. Fifty microliters of IS were added in each tube. The tubes were capped and mixed as described above. Eight hundred microliters of extraction reagent (acetonitrile) were added to each tube. This solution was capped and mixed by vortexing at high speed setting for 30 s. Next, all tubes were centrifuged at 10,000g for 10 min in an eppendorf microcentrifuge. After centrifugation, the upper organic layer was filtered through a 0.2-mm membrane into a clean eppendorf microcentrifuge tube and a volume of 20 mL was injected into the HPLC system.
Preparation of curcumin-loaded HPC nanoparticles
Curcumin-loaded HPC nanoparticles were formulated employing the solvent emulsion evaporation technique. To describe in brief, HPC (10 mg) and curcumin (20 mg) were dissolved in a mixture of tetrahydrofuran (3 mL) and dichloromethane (3 mL). PVP (0.15%, w/v) and Poloxamer 188 (0.1%, w/v) were dissolved in water (20 mL). The organic and aqueous solutions were then emulsified utilizing Ultraturrax T25 (Janke & Kunkel, IKA Labortechnik, Staufen, Germany) at 13,000 g for 5 min. Subsequently, the nanoparticles were formed by evaporating the organic phase at room temperature (30 + 38C) using a blade-type stirrer (Remi, Mumbai, India) at 900 g for 8 h.
Method validation procedures
The method was validated for selectivity, precision, accuracy, linearity, LLOQ and extraction efficiency, according to the International Conference on Harmonization (20) and Food and Drug Administration (FDA) guidelines (21) .
LLOQ
The LLOQ was determined as the lowest concentration on the standard calibration curve, which can be quantitatively determined with a precision of 20% and accuracy of 80-120% (20, 21) .
Linearity
The linearity study was performed by injecting a total of seven calibration standard solutions (10-1000 ng/mL) covering the working range of the assay. The calibration curves were constructed by plotting peak area ratios of curcumin to IS against corresponding concentrations. The calibration model was accepted if (i) the coefficient of correlation was greater than or equal to 0.98 and/or (ii) residuals were within +20% at the LLOQ and within +15% at all other calibration levels (21) . Five calibration curves were prepared from a blank sample (matrices samples processed with the IS), including the LLOQ. The slope and the Y intercept of the calibration curve were calculated.
Selectivity
The selectivity of a bioanalytical method is generally defined as the lack of interfering peaks at the retention times of the assayed drug and the IS in the chromatogram (20) . The selectivity of the assay was investigated by processing and analyzing blanks prepared from six independent lots of plasma sample controls.
Precision and accuracy
Intra-and interday precision and accuracy of the method was performed by conducting replicate (n ¼ 6) analysis of QC samples in plasma (LLOQC (10 ng/mL), LOQC (50 ng/mL), MQC (250 ng/mL) and HQC (1000 ng/mL)) against a calibration curve. This procedure was replicated on different days (n ¼ 3). Precision was calculated from the percentage relative standard deviation (% RSD) for the repeated measurements, whereas accuracy was determined by calculating the percent difference (bias %) between the measured mean concentrations and the corresponding nominal concentrations. According to the FDA criteria (20) , precision and accuracy determined at each concentration level should not exceed 15% except for the LLOQ, which should not deviate by more than 20%.
Extraction efficiency
The mean recovery of curcumin and IS from spiked human plasma was evaluated to test the efficiency and reproducibility of the extraction procedure. The determination of the extraction efficiency in plasma was made by injecting replicates at the concentration ranges of LLOQC, LOQ, MQC and HQC. The extraction was conducted as described previously. The responses of these standards, taken by means of the extraction procedures, have been compared with those of standard solution at the same concentration injected directly into the HPLC. The peak area ratios were compared with the ratio of the standard aqueous samples without extraction.
Stability studies
Drug stability in biological matrices is a function of the storage conditions, the chemical properties of the drug and the matrix (20) . For all stability studies, LLOQC, LOQC, MQC and HQC samples (10, 50, 250 and 1000 ng/mL, respectively) were used in triplicate.
The stability at room temperature, solution stability and extract stability for the analyte and for the IS were determined upto 6 h. Further, to determine storage stability of analyte in plasma, the freeze-thaw stability of curcumin was evaluated at 48C and 2258C over three freeze -thaw cycles (15 days). The samples prepared on day 0 were stored at 4 and 2258C, respectively. At each freeze-thaw cycle, the samples were removed from the cold storage chamber, were thawed to room temperature and were further analyzed by HPLC. The concentration of curcumin after each test condition was compared with the initial concentration added to the sample on Day 0 (Cycle 0). The rats were fasted overnight before dosing and were randomly divided into two groups of 5 each. One group of rats received curcumin-loaded HPC nanoparticles dispersed in double-distilled water (equivalent to 100 mg/kg curcumin) and the other group was given curcumin suspension (100 mg/kg curcumin) orally. Blood ( 0.5 mL) was collected from retro orbital plexus of rat in a tube containing saturated solution of di-sodium EDTA at pre-dose, and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 12 and 24 h postdosing for curcumin-loaded HPC nanoparticles and 0.25, 0.5, 1, 1.5 h postdosing for curcumin suspension. After each sampling, 1 mL of dextrose-normal saline was administered to prevent changes in the central compartment volume and electrolyte balance. Immediately after collection, blood samples were gently inverted several times to ensure complete mixing with the di-sodium EDTA solution. Blood samples were then centrifuged at 10,000 g for 5 min and plasma was separated followed by extraction with acetonitrile and were analyzed by HPLC for curcumin concentration.
Pharmacokinetic analysis
Statistical analysis
Data of in vivo analysis were expressed as mean + SD (n ¼ 5). The data were compared for statistical significance by one-way analysis of variance followed by the Tukey -Kramer multiple comparisons test using the Graph Pad Instat software (Graph Pad Software Inc., CA, USA).
Results
Method development
According to the chemical characteristics of curcumin and IS, 1% concentration of acetic acid and 50% triethanolamine added into mobile phase was necessary for good peak shapes. It was found that a mixture of acetonitrile: 1% acetic acid ( pH 3 adjusted with 50% TEA) (45:55, v/v) could serve the above purpose and was finally adopted as the mobile phase. In our early study, several kinds of columns were compared, such as Zorbax Eclipse C18 (4.6 Â 150 mm, 5 mm), Hypersil BDS C 18 (4.6 Â 150 mm, 5 mm) and Hypersil ODS C 18 (4.6 Â 150 mm, 5 mm). However, the retention time of curcumin was longer and the peaks were not sharp enough. After careful comparison, Zorbax Eclipse C 18 (4.6 Â 150 mm, 5 mm) was finally used with a flow rate of 1.25 mL/min to obtain sharp peak shapes, high recovery and good validation and permit a run time of 9 min.
LLOQ
The linear regression analysis of curcumin was constructed by plotting the peak area ratio of curcumin to IS versus the concentration of curcumin in ng/mL. The calibration curve was highly linear (r 2 . 0.999) within the range 10 -1000 ng/mL for curcumin extracted from human plasma samples (Figure 2) . Typical values for the regression parameters a (the slope) and b (the Y intercept) were calculated to be 0.0056 and 0.0597, respectively. The LLOQ of curcumin was determined to be 10 ng/ mL in human plasma.
Selectivity
Curcumin and IS were well separated and were identified by their relative retention time, i.e. 1.4 + 0.1 and 8.2 + 0.2 min, respectively. Chromatograms of blank human plasma against those spiked with zero sample (IS along with plasma) and with curcumin and IS are expressed in Figure 3a -c. The chromatogram of a plasma sample from a rat that received 100 mg/kg of curcumin orally is shown in Figure 4a and b.
Precision and accuracy Intra-and interday precision and accuracy of the method was performed by conducting replicate (n ¼ 6) analysis of QC samples in plasma (LLOQC (10 ng/mL), LOQC (50 ng/mL), MQC (250 ng/mL) and HQC (1000 ng/mL)) against a calibration curve. The mean concentration found and the RSD values of precision and accuracy are shown in Tables I and II, respectively.
Extraction efficiency
The absolute recovery of curcumin from plasma was determined by comparing the peak area obtained from extracts of spiked plasma samples with that obtained from the direct injection of known amounts of standard solutions of curcumin. Extraction efficiency was assessed at the concentration of 10, 50, 250 and 1000 ng/mL using three replicates at each concentration. The extraction efficiencies of curcumin and IS are reported in Table III .
Stability studies
Four sets of plasma samples at the levels of LLOQC, LOQC, MQC and HQC were subjected to stability studies, and the results of stability at room temperature, 4 and 2258C are reported in Tables IV-VI respectively.
Application to pharmacokinetic analysis
Plasma profiles of curcumin in rats following oral administration of the curcumin suspension and curcumin-loaded HPC nanoparticles are shown in Figure 5 , whereas pharmacokinetic parameters in plasma obtained from the pooled concentration-time data are listed in Table VII . As determined by the HPLC method, the AUC 0!t of curcumin-loaded HPC nanoparticles was 489.093 + 39.88 ng h/mL, while the AUC 0!t of orally administered 
Discussion
The HPLC procedure was optimized with a view to developing a bioanalytical method to quantify curcumin in the presence of IS from human plasma. Therefore, the detection wavelength was set at 425 nm. It was necessary to use an IS in extraction techniques and HPLC method to compensate for extraction variation, efficiency and analytical errors. Berberine was adopted as an IS in this study because it is structurally similar to curcumin and its behavioral characteristics and properties conform to the chemical requirement for IS in HPLC (19) . In addition, berberine is commercially available in high purity, and it is stable and nonreactive with sample or mobile phase. Moreover, it also has good response at a detection wavelength of 425 nm. The mobile phase was optimized through several trials to achieve good resolution and symmetric peak shapes for both analyte and IS. Acetonitrile has the least viscosity compared with tetrahydrofuran and methanol, and it has strong eluting power. Therefore, it was selected as organic phase. Further, it must be noted that the significantly high linearity (r 2 .0.999) and low variability (.11.48%) resulted in highly sensitive method with the LLOQ of 10 ng/mL. Selectivity was demonstrated by the absence of any endogenous interference at retention times of peaks of interest as evaluated by chromatograms of blank human plasma, zero sample and nonzero sample. The RSD values of intra -and interday studies varied from 1.1 to 12.21%, indicating that the intermediate precision of the method was satisfactory. The RSD values of intra-and interday accuracy varied from 0.16 to 13.26%, indicating the accuracy of a method is expressed as the closeness of agreement between the observed value and the value that is accepted as a reference value. The extraction efficiency was 100%, which proved the suitability of this extraction method for the analysis of plasma samples. Curcumin was proved to be stable at room temperature in plasma for 6 h and freeze-thaw results suggested that at 48C and at2258C curcumin was stable in plasma up to 24 h without any curcumin degradation, after which the gradual degradation commences. Thus, if stored at a lower temperature, samples must be analyzed within 24 h. Curcumin-loaded HPC nanoparticles exhibited 43.73-fold higher bioavailability, 3.51 times greater C max and 27.25 times higher T 1/2 compared with curcumin suspension. The evidence (as determined through LC) suggests the protective role of HPC nanoparticles as a carrier system to deliver curcumin in the systemic circulation and thus improving its bioavailability upon oral administration. Besides, HPC nanoparticles prolong the residence time in GIT due to their swelling and bioadhesive nature.
Conclusion
A simple, rapid and sensitive HPLC method was developed and validated for the determination of curcumin in human plasma. The sensitivity of the method allowed the pharmacokinetic study of curcumin in plasma after oral administration of curcuminloaded HPC nanoparticles and curcumin suspension in female Wistar rats. Curcumin-loaded HPC nanoparticles significantly improved the pharmacokinetic profile of the drug administered to rats. Furthermore, the sensitivity of the established method provides a reliable bioanalytical methodology to carry out tissue distribution of curcumin. 
